Quantcast

Latest Clinical trial Stories

2014-09-26 08:25:31

SAN FRANCISCO, Sept. 26, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of MOVENTIG® (naloxegol) for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxatives. MOVENTIG is an investigational, peripherally-acting...

2014-09-25 16:26:01

BOSTON, Sept. 25, 2014 /PRNewswire/ -- GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced today that has initiated dosing of healthy volunteers in a first-in-human Phase 1a clinical trial of its lead product candidate, GC021109, a novel compound developed as a disease-modifying treatment for Alzheimer's disease. In pre-clinical animal studies GC021109 has...

2014-09-25 08:27:51

GLEN BURNIE, Md., Sept. 25, 2014 /PRNewswire/ -- CSSi (www.CSSiEnroll.com), the leader in patient recruitment solutions for the clinical research industry, is pleased to announce the recent appointment of two new hires, adding significant value and expertise to its offerings. CSSi has named Greg Fleming as Director of Business Development and Gemma Groppi as Senior Global Project Manager. Greg will be based on the West Coast working out of CSSi's San Francisco office while Gemma will...

2014-09-25 08:27:37

University of Toledo's Dr. Sharrel Pinto to Lead Study Using MTS Adherence Packaging Solutions from Omnicell MOUNTAIN VIEW, Calif., Sept. 25, 2014 /PRNewswire/ -- Omnicell® Inc. today announced the commencement of the STOMPP (Study the Effect of a Hybrid Pharmacy Practice Model on Medication Adherence) clinical study. The evaluation is led by Dr. Sharrel Pinto, Division Head and Associate Professor in the Health Outcomes and Socioeconomic Sciences Division and Research Director of the Center...

2014-09-25 08:27:08

MINNETONKA, Minn., Sept. 25, 2014 /PRNewswire/ -- Zyga Technology, Inc., a developer of minimally invasive solutions for underserved areas in spine, announced today that it has completed a $10 million round of financing. The company intends to use the proceeds to fund the expansion of its U.S. sales and marketing organization as it prepares for the implementation of a Category 1 CPT code for SI joint fusion procedures in January 2015. In addition, the financing will also be used to support...

2014-09-24 08:28:14

New addition expands WCG's eClinical offerings for improving clinical trial start-up and management PRINCETON, N.J., Sept. 24, 2014 /PRNewswire/ -- WIRB-Copernicus Group (WCG), the world's largest provider of regulatory and ethical review services for clinical research, announced today that ePharmaSolutions (ePS) has joined its group of companies. Based near Philadelphia, PA, ePS is a leading provider of eClinical solutions and technology-enabled services that improve the conduct of...

2014-09-23 23:01:00

PhUSE, the biggest membership driven community in the biometrical sector of the pharmaceutical industry, continues its global expansion and organizes single day events which will be held this fall in Japan, China and India. (PRWEB) September 24, 2014 The inaugural single day event in Japan will be held October 31st in the Hotel New Otani Tokyo Gardens in Tokyo. Clinical data scientists will meet and discuss various topics about standard data implementation and validation. The second...

2014-09-23 08:30:43

Enrollment in Worldwide Trial Continues as Planned REDMOND, Wash., Sept. 23, 2014 /PRNewswire/ -- Cerevast Therapeutics Inc., a privately held medical technology company, announced today the outcome of the first interim analysis of its ongoing Phase 3 clinical trial evaluating the Company's proprietary Clotbust ER(TM) ultrasonic headframe for the treatment of acute ischemic stroke. The independent Data Safety Monitoring Board (DSMB) has recommended the trial continue enrollment as...

2014-09-23 04:21:52

CAMBRIDGE, England, September 23, 2014 /PRNewswire/ -- New spin-out from Cancer Research UK launched with funding from Imperial Innovations, Cambridge Innovation Capital and Johnson & Johnson Development Corporation Inivata, a clinical cancer genomics company focused on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment, today announced it has raised GBP4m in a funding round led by Imperial Innovations...

2014-09-22 12:31:25

PINE BROOK, N.J., Sept. 22, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in development for the treatment of inhalational anthrax and data from these studies support the safety and tolerability of the antitoxin when administered intravenously...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related